What Next for resTORbio, Inc. (TORC) Stock After Touching All-Time Low?

March 14, 2018 - By Maria Brooks

The stock of resTORbio, Inc. (NASDAQ:TORC) reached all time low today, Mar, 14 and still has $14.59 target or 6.00 % below today’s $15.52 share price. This indicates more downside for the $421.95 million company. This technical setup was reported by Barchart.com. If the $14.59 PT is reached, the company will be worth $25.32 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock increased 0.42% or $0.07 during the last trading session, reaching $15.52. About 212,086 shares traded or 16.55% up from the average. resTORbio, Inc. (NASDAQ:TORC) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

More notable recent resTORbio, Inc. (NASDAQ:TORC) news were published by: Seekingalpha.com which released: “IPO approaches for resTORbio” on January 02, 2018, also Businesswire.com with their article: “resTORbio Raises $40 Million to Advance Selective TORC1 Inhibitors for Aging …” published on November 30, 2017, Businesswire.com published: “resTORbio Advances to Part 2 of a Phase 2b Clinical Study of RTB101 …” on November 20, 2017. More interesting news about resTORbio, Inc. (NASDAQ:TORC) were released by: Businesswire.com and their article: “resTORbio Appoints Joan Mannick, MD, as Chief Medical Officer” published on April 13, 2017 as well as Businesswire.com‘s news article titled: “resTORbio Appoints Paul Fonteyne to Its Board of Directors” with publication date: December 11, 2017.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The company has market cap of $421.95 million. The Company’s lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. It currently has negative earnings. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: